Quest PharmaTech (CVE:QPT) Trading Down 25% – Here’s Why

Quest PharmaTech Inc. (CVE:QPT) was down 25% on Thursday . The stock traded as low as C$0.03 and last traded at C$0.03. Approximately 123,238 shares traded hands during trading, an increase of 414% from the average daily volume of 23,982 shares. The stock had previously closed at C$0.04.

Quest PharmaTech Stock Performance

The company has a debt-to-equity ratio of 4.35, a current ratio of 0.40 and a quick ratio of 0.52. The business has a 50-day moving average of C$0.04 and a 200-day moving average of C$0.04. The company has a market capitalization of C$5.07 million, a P/E ratio of -30.00 and a beta of 0.00.

Quest PharmaTech Company Profile

Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class.